Workflow
脊髓刺激器(SCS)
icon
Search documents
研判2025!中国神经调节行业产业链、市场规模及重点企业分析:以精准神经调控革新治疗范式,重塑患者生活质量新标准[图]
Chan Ye Xin Xi Wang· 2025-10-10 01:33
Core Insights - Neuromodulation technology shows significant advantages in treating neurological diseases such as epilepsy and Parkinson's disease, enhancing treatment effectiveness and improving patients' quality of life [1][8] - The Chinese neuromodulation industry is projected to reach a market size of approximately 2.285 billion yuan in 2024, reflecting a year-on-year growth of 8.65%, driven by technological innovation and market demand [1][8] Industry Overview - Neuromodulation is a treatment method that regulates nervous system activity through electrical, magnetic, chemical, or other forms of stimulation, aiming to alleviate symptoms and improve functionality [2] - The industry can be categorized into invasive and non-invasive techniques, each comprising various specific technologies [2] Industry Development History - The Chinese neuromodulation industry has evolved over seventy years, starting from foundational research in the 1950s to the current stage of mature expansion, with significant milestones in technology introduction and innovation [2][3] - Key developments include the first DBS surgery in 1998 and the establishment of the first domestic DBS product registration in 2013, marking a shift from technology importation to independent innovation [2][3] Market Size - The neuromodulation market is expected to grow to approximately 2.285 billion yuan in 2024, with an 8.65% increase from the previous year, indicating a dual driving effect of technology transformation and market demand [1][8] Key Companies - Beijing Pincai Medical holds over 25% of the domestic market share with its comprehensive range of neuromodulation products, including DBS and SCS [9][10] - Suzhou Jingyu Medical is a leading player in the DBS field, having received FDA breakthrough device designation for its dual-target DBS technology [10][11] Industry Development Trends 1. Continuous integration of technological innovations will drive precision and intelligent upgrades in the neuromodulation sector, with advancements in AI and brain-computer interfaces expected to enhance treatment efficacy [12] 2. Application scenarios are expanding from traditional disease treatment to cognitive enhancement and emotional regulation, with consumer-grade neuromodulation devices anticipated to see explosive growth [13][14] 3. Policy and industry collaboration will promote domestic production and global expansion, with ongoing government support for brain science initiatives and the inclusion of neuromodulation procedures in insurance reimbursement [15]